Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company in the US, has announced that it has received a new market approval from the National Medical Products Administration (NMPA) in China for its drug Mounjaro (tirzepatide) as a long-term weight management treatment. Administered as a once-weekly injection, Mounjaro is set to play a significant role in the weight management space in China.
In May this year, tirzepatide became the first dual GIP/GLP-1 receptor agonist to be introduced to the Chinese market, gaining approval as a treatment for type 2 diabetes mellitus (T2DM) patients with poor blood glucose control despite treatment with metformin or sulfonylurea drugs. The drug’s mechanism of action involves binding to and activating GIP and GLP-1 receptors, which reduces food intake, induces weight loss, and decreases fat mass by regulating appetite.
Mounjaro is indicated for long-term weight management in adults with a body mass index (BMI) of ≥ 28 kg/m2 (obesity) or ≥ 24 kg/m2 (overweight) who have at least one weight-related complication, such as hypertension, dyslipidemia, hyperglycemia, obstructive sleep apnea, or cardiovascular disease. The drug is intended for use in conjunction with dietary and exercise measures to help individuals achieve and maintain a healthy weight.- Flcube.com
